NCT00210951View on ClinicalTrials.gov

Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin

CompletedOBSERVATIONAL
Enrollment

4,761

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Red-Cell Aplasia, PureChronic Renal Failure
Interventions
OTHER

No Intervention

Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210951 - Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin | Biotech Hunter | Biotech Hunter